Urothelial Cancer Drugs Market Size, Share & Trends Analysis Report By Treatment Class (Chemotherapy, Immunotherapy), By Major Markets, Competitive Landscape, And Segment Forecasts, 2018 - 2023
This report can be delivered to the clients within 24 Business Hours
The global urothelial cancer drugs market size is expected to reach USD 3.6 billion by 2023, as per a new report by Grand View Research, Inc., exhibiting a 22.9% CAGR during the forecast period. Availability of novel drugs, presence of a strong pipeline, rising disease incidence, unhealthy lifestyle, and increasing awareness are driving this market.
Urothelial cancer is the ninth most common malignancy in the world, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Approximately 59% of bladder cancer cases occur in developed regions such as North America and Europe. The disease has the highest lifetime cost of care per patient among all tumors in U.S. due to its high relapse rate and invasive lifelong monitoring including cystoscopy follow-ups.
Bladder transitional cell carcinoma (TCC) is the most common histology, accounting for nearly 90% of all urinary cancer cases. Urothelial cancer is clinically divided into three categories: non-muscle invasive bladder cancer (NMIBC, early stage), muscle invasive disease (MIBC, mid stage), and metastatic disease (late stage). At diagnosis, approximately 70% of cases are non-muscle invasive disease, 20% are at the muscle invasive stage, and 10% are at the advanced stage.
Further key findings from the report suggest:
The global urothelial cancer drugs market size is expected to reach USD 3.6 billion by 2023, as per a new report by Grand View Research, Inc., exhibiting a 22.9% CAGR during the forecast period. Availability of novel drugs, presence of a strong pipeline, rising disease incidence, unhealthy lifestyle, and increasing awareness are driving this market.
Urothelial cancer is the ninth most common malignancy in the world, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Approximately 59% of bladder cancer cases occur in developed regions such as North America and Europe. The disease has the highest lifetime cost of care per patient among all tumors in U.S. due to its high relapse rate and invasive lifelong monitoring including cystoscopy follow-ups.
Bladder transitional cell carcinoma (TCC) is the most common histology, accounting for nearly 90% of all urinary cancer cases. Urothelial cancer is clinically divided into three categories: non-muscle invasive bladder cancer (NMIBC, early stage), muscle invasive disease (MIBC, mid stage), and metastatic disease (late stage). At diagnosis, approximately 70% of cases are non-muscle invasive disease, 20% are at the muscle invasive stage, and 10% are at the advanced stage.
Further key findings from the report suggest:
- The U.S. dominated the urothelial cancer market, with more than 60% of the market in 2017. Several factors such as presence of a large target population, increased adoption of novel therapeutics, and multiple product launches will drive the market in this region
- The therapeutic landscape is expected to witness a paradigm shift toward combination therapies and novel immuno-oncology products. Combination regimens, particularly checkpoint inhibitors, are likely to be introduced in the first-line setting. Immune checkpoint blockade therapy is expected to replace the current standard of care in bladder cancer in the foreseeable future
- Therapeutic development in second-line setting for chemotherapy-intolerant patients is expected to have a major impact in the urothelial cancer space
- Urothelial cancer presents a strong opportunity for introducing first-in-class treatments due to high unmet needs. Opportunities remain in the non-muscle invasive bladder cancer (NMIBC) setting where there exists an unmet need for treatment options for patients who are BCG-intolerant or ineligible
- Some of the key players operating in this market are Roche, Merck, Bristol-Myers Squibb, AstraZeneca, and Pfizer.
CHAPTER 1 RESEARCH METHODOLOGY
1.1. Information Procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. Disease Primer
3.2. Epidemiology
CHAPTER 4 GLOBAL UROTHELIAL CANCER DRUGS MARKET OVERVIEW
4.1 Market by Treatment Class
4.2 Market Size and Forecast 2017- 2023
4.3 Market Share Distribution, by Company 2017- 2023
4.4 Market Dynamics and Brand Strategies
4.5 Patent Expiry Analysis
4.6 Urothelial Cancer Market: Drivers and Restraints
4.6.1 Drivers
4.6.2 Challenges
4.7 M&A, Deal Landscape (2013-2018 YTD)
4.7.1 Mergers & Acquisitions
4.7.2 Deals Landscape
4.8 Emerging Markets
4.9 Reimbursement Scenario
4.10 Urothelial Cancer Sector SWOT
CHAPTER 5 UROTHELIAL CANCER DRUGS MARKET: PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Merck
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales Through 2023
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Roche
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales Through 2023
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.4.2 Catalysts & Events Calendar
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Bristol-Myers Squibb
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2023
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 Pipeline Analysis & Overview
6.3.6 SWOT
6.4 AstraZeneca
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2023
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.4.2 Catalysts & Events Calendar
6.4.5 Pipeline Analysis & Overview
6.4.6 SWOT
6.5 Pfizer
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales Through 2023
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.4.2 Catalysts & Events Calendar
6.5.5 Pipeline Analysis & Overview
6.5.6 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead
1.1. Information Procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. Disease Primer
3.2. Epidemiology
CHAPTER 4 GLOBAL UROTHELIAL CANCER DRUGS MARKET OVERVIEW
4.1 Market by Treatment Class
4.2 Market Size and Forecast 2017- 2023
4.3 Market Share Distribution, by Company 2017- 2023
4.4 Market Dynamics and Brand Strategies
4.5 Patent Expiry Analysis
4.6 Urothelial Cancer Market: Drivers and Restraints
4.6.1 Drivers
4.6.2 Challenges
4.7 M&A, Deal Landscape (2013-2018 YTD)
4.7.1 Mergers & Acquisitions
4.7.2 Deals Landscape
4.8 Emerging Markets
4.9 Reimbursement Scenario
4.10 Urothelial Cancer Sector SWOT
CHAPTER 5 UROTHELIAL CANCER DRUGS MARKET: PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Merck
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales Through 2023
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Roche
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales Through 2023
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.4.2 Catalysts & Events Calendar
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Bristol-Myers Squibb
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2023
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 Pipeline Analysis & Overview
6.3.6 SWOT
6.4 AstraZeneca
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2023
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.4.2 Catalysts & Events Calendar
6.4.5 Pipeline Analysis & Overview
6.4.6 SWOT
6.5 Pfizer
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales Through 2023
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.4.2 Catalysts & Events Calendar
6.5.5 Pipeline Analysis & Overview
6.5.6 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead
LIST OF TABLES
Table 1 Incidence Rate per 100,000 in Seven Major Markets
Table 2 Marketed Drugs for Urothelial Cancer
Table 3 Sales Performance by Treatment Type, 2017 -
Table 4 Sales Performance by Market, in $ million, 2017 - 2023
Table 5 Patents Expiry for Current Urothelial Cancer Drugs
Table 6 R&D Pipeline Overview
Table 7 Late Stage Pipeline
Table 8 Epacadostat
Table 9 Erdafitnib
Table 10 Cyramza
Table 11 Pipeline Forecast
Table 12 Merck Sales Forecast, 2017 - 2023
Table 13 Merck Pipeline
Table 14 Roche Sales Forecast, 2017 - 2023
Table 15 Roche Pipeline
Table 16 Bristol-Myers Squibb Sales Forecast, 2017 - 2023
Table 17 Bristol-Myers Squibb Pipeline
Table 18 Astrazeneca Sales Forecast, 2017 - 2023
Table 19 AstraZeneca Pipeline
Table 20 Pfizer Sales Forecast, 2017 - 2023
Table 21 Pfizer Pipeline
Table 1 Incidence Rate per 100,000 in Seven Major Markets
Table 2 Marketed Drugs for Urothelial Cancer
Table 3 Sales Performance by Treatment Type, 2017 -
Table 4 Sales Performance by Market, in $ million, 2017 - 2023
Table 5 Patents Expiry for Current Urothelial Cancer Drugs
Table 6 R&D Pipeline Overview
Table 7 Late Stage Pipeline
Table 8 Epacadostat
Table 9 Erdafitnib
Table 10 Cyramza
Table 11 Pipeline Forecast
Table 12 Merck Sales Forecast, 2017 - 2023
Table 13 Merck Pipeline
Table 14 Roche Sales Forecast, 2017 - 2023
Table 15 Roche Pipeline
Table 16 Bristol-Myers Squibb Sales Forecast, 2017 - 2023
Table 17 Bristol-Myers Squibb Pipeline
Table 18 Astrazeneca Sales Forecast, 2017 - 2023
Table 19 AstraZeneca Pipeline
Table 20 Pfizer Sales Forecast, 2017 - 2023
Table 21 Pfizer Pipeline
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Urothelial Cancer Drugs Market Share, by Treatment Type, 2017 &
Fig. 8 Regional Market Size, 2017 & 2023
Fig. 9 U.S. Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 10 U.K. Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 11 Germany Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 12 Italy Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 13 Spain Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 14 France Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 15 Japan Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 16 Market Shares Distribution, 2017&2023
Fig. 17 Urothelial Cancer SWOT
Fig. 18 Urothelial Cancer Pipeline Distribution
Fig. 19 Merck UC Sales Forecast
Fig. 20 Merck SWOT Analysis
Fig. 21 Roche UC Sales Forecast
Fig. 22 Roche SWOT Analysis
Fig. 23 Bristol-Myers Squibb UC Sales Forecast
Fig. 24 Bristol-Myers Squibb SWOT Analysis
Fig. 25 AstraZeneca UC Sales Forecast
Fig. 26 AstraZeneca SWOT Analysis
Fig. 27 Pfizer UC Sales Forecast
Fig. 28 Pfizer SWOT Analysis
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Urothelial Cancer Drugs Market Share, by Treatment Type, 2017 &
Fig. 8 Regional Market Size, 2017 & 2023
Fig. 9 U.S. Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 10 U.K. Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 11 Germany Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 12 Italy Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 13 Spain Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 14 France Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 15 Japan Urothelial Cancer Drugs Market, $ million (2017 - 23)
Fig. 16 Market Shares Distribution, 2017&2023
Fig. 17 Urothelial Cancer SWOT
Fig. 18 Urothelial Cancer Pipeline Distribution
Fig. 19 Merck UC Sales Forecast
Fig. 20 Merck SWOT Analysis
Fig. 21 Roche UC Sales Forecast
Fig. 22 Roche SWOT Analysis
Fig. 23 Bristol-Myers Squibb UC Sales Forecast
Fig. 24 Bristol-Myers Squibb SWOT Analysis
Fig. 25 AstraZeneca UC Sales Forecast
Fig. 26 AstraZeneca SWOT Analysis
Fig. 27 Pfizer UC Sales Forecast
Fig. 28 Pfizer SWOT Analysis
